Reversible Suppression of Hypothalamo-pituitary-adrenal Axis in Addison's Disease Due to Ethinyl Oestradiol-induced Increase in Total Cortisol

Overview

Journal Endocrinol Diabetes Metab Case Rep

Specialty Endocrinology

Date 2024 Dec 19

PMID 39700335

Authors

Krzysztof C Lewandowski

Monika Gluchowska

Malgorzata Karbownik-Lewinska

Andrzej Lewinski

Affiliations

Soon will be listed here.

Abstract

Summary: An oral contraceptive pill (OCP)-induced increase in total cortisol lead to reversible suppression of the hypothalamic-pituitary-adrenal (HPA) axis and insulin resistance (IR) in a patient with Addison's disease. We suggest that this might influence the choice of an OCP in such patients. A 20-year-old female was diagnosed with Addison's disease (cortisol: 44 nmol/L, adrenocorticotropic hormone (ACTH): >500 pg/mL) and started on hydrocortisone (HC). Few months later, an OCP (30 μg ethinyl oestradiol (EE) and 3 mg drospirenone) was added. Total cortisol was above the upper assay detection limit (UADL), while ACTH was inappropriately 'normal': cortisol 8:00 (pre-dose) 83 nmol/L, post-dose 10:00 >1757 nmol/L, ACTH 8:00 (pre-dose) 24.1 pg/mL and post-dose 10:00 3.8 pg/mL. Even 5 mg of oral HC induced an increase in cortisol above UADL. The glucagon stimulation test (GST) showed brisk growth hormone secretion. The corticotropin-releasing hormone (CRH) test showed partial hypothalamic suppression of CRH release: minimal ACTH 42.4 pg/mL and maximal ACTH 87.3 pg/mL, i.e. relatively low levels for all cortisol concentrations <69 nmol/L. Withdrawal of the OCP resulted in the return of high ACTH concentrations typical for patients with Addison's disease on HC replacement. There was also a marked improvement in insulin resistance (a fall in homeostasis model assessment - insulin resistance (HOMA-IR) from 3.64 to 1.69 and a marked decline in mean insulin concentrations during GST). EE administration resulted in a massive increase in total cortisol with suppression of the HPA axis and IR suggestive of relative hypercortisolaemia. This raises the question of whether EE should be avoided as a contraceptive agent in women with adrenal failure.

Learning Points: An OCP containing 30 μg EE induced relative and reversible hypercortisolaemia in a patient with Addison's disease with evidence of suppression of ACTH secretion on dynamic pituitary function tests.We suggest that, in some patients with adrenal failure, EE administration may lead to unrecognised relative hypercortisolaemia and IR.There is literature evidence that, in patients with Addison's disease, EE may decrease cortisol clearance.These alterations are reversible upon EE withdrawal and may have implications for the choice of a contraceptive agent in women with Addison's disease.

References

Brien T . Cortisol metabolism after oral contraceptives: total plasma cortisol and the free cortisol index. Br J Obstet Gynaecol. 1975; 82(12):987-91. DOI: 10.1111/j.1471-0528.1975.tb00609.x. View

Raff H, Carroll T . Cushing's syndrome: from physiological principles to diagnosis and clinical care. J Physiol. 2014; 593(3):493-506. PMC: 4324701. DOI: 10.1113/jphysiol.2014.282871. View

Thomson A, Devers M, Wallace A, Grant D, Campbell K, Freel M . Variability in hydrocortisone plasma and saliva pharmacokinetics following intravenous and oral administration to patients with adrenal insufficiency. Clin Endocrinol (Oxf). 2007; 66(6):789-96. DOI: 10.1111/j.1365-2265.2007.02812.x. View

Dichtel L, Schorr M, Loures de Assis C, Rao E, Sims J, Corey K . Plasma Free Cortisol in States of Normal and Altered Binding Globulins: Implications for Adrenal Insufficiency Diagnosis. J Clin Endocrinol Metab. 2019; 104(10):4827-4836. PMC: 6735741. DOI: 10.1210/jc.2019-00022. View

Lewandowski K, Malicka K, Dabrowska K, Lewinski A . Addison's disease concomitant with corticotropin deficiency and pituitary CRH resistance - a case report. Endokrynol Pol. 2017; 68(4):468-471. DOI: 10.5603/EP.2017.0052. View

Peacey S, Guo C, Robinson A, Price A, Giles M, Eastell R . Glucocorticoid replacement therapy: are patients over treated and does it matter?. Clin Endocrinol (Oxf). 1997; 46(3):255-61. DOI: 10.1046/j.1365-2265.1997.780907.x. View

Agren U, Anttila M, Maenpaa-Liukko K, Rantala M, Rautiainen H, Sommer W . Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in comparison to one containing levonorgestrel and ethinylestradiol on markers of endocrine function. Eur J Contracept Reprod Health Care. 2011; 16(6):458-67. PMC: 3233273. DOI: 10.3109/13625187.2011.614363. View

Klipping C, Duijkers I, Mawet M, Maillard C, Bastidas A, Jost M . Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone. Contraception. 2021; 103(4):213-221. DOI: 10.1016/j.contraception.2021.01.001. View

Mazziotti G, Formenti A, Frara S, Roca E, Mortini P, Berruti A . MANAGEMENT OF ENDOCRINE DISEASE: Risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects. Eur J Endocrinol. 2017; 177(5):R231-R248. DOI: 10.1530/EJE-17-0154. View

10.

Sandberg A, SLAUNWHITE Jr W . Transcortin: a corticosteroid-binding protein of plasma. II. Levels in various conditions and the effects of estrogens. J Clin Invest. 1959; 38(8):1290-7. PMC: 442083. DOI: 10.1172/JCI103904. View

11.

Kumsta R, Entringer S, Hellhammer D, Wust S . Cortisol and ACTH responses to psychosocial stress are modulated by corticosteroid binding globulin levels. Psychoneuroendocrinology. 2007; 32(8-10):1153-7. DOI: 10.1016/j.psyneuen.2007.08.007. View

12.

Mah P, Jenkins R, Rostami-Hodjegan A, Newell-Price J, Doane A, Ibbotson V . Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clin Endocrinol (Oxf). 2004; 61(3):367-75. DOI: 10.1111/j.1365-2265.2004.02106.x. View

13.

Westhoff C, Petrie K, Cremers S . Using changes in binding globulins to assess oral contraceptive compliance. Contraception. 2012; 87(2):176-81. PMC: 3494777. DOI: 10.1016/j.contraception.2012.06.003. View

14.

Kangasniemi M, Arffman R, Haverinen A, Luiro K, Hustad S, Heikinheimo O . Effects of estradiol- and ethinylestradiol-based contraceptives on adrenal steroids: A randomized trial. Contraception. 2022; 116:59-65. DOI: 10.1016/j.contraception.2022.08.009. View

15.

Wiegratz I, Kuhl H . Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins. Contraception. 1995; 51(6):341-6. DOI: 10.1016/0010-7824(95)00098-u. View

16.

Perogamvros I, Underhill C, Henley D, Hadfield K, Newman W, Ray D . Novel corticosteroid-binding globulin variant that lacks steroid binding activity. J Clin Endocrinol Metab. 2010; 95(10):E142-50. DOI: 10.1210/jc.2010-0746. View

17.

Tunn S, Mollmann H, Barth J, Derendorf H, Krieg M . Simultaneous measurement of cortisol in serum and saliva after different forms of cortisol administration. Clin Chem. 1992; 38(8 Pt 1):1491-4. View

18.

Perogamvros I, Aarons L, Miller A, Trainer P, Ray D . Corticosteroid-binding globulin regulates cortisol pharmacokinetics. Clin Endocrinol (Oxf). 2010; 74(1):30-6. DOI: 10.1111/j.1365-2265.2010.03897.x. View

19.

Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R . Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7):412-9. DOI: 10.1007/BF00280883. View